Information Provided By:
Fly News Breaks for April 10, 2018
PCRX, HRTX
Apr 10, 2018 | 06:01 EDT
Mizuho analyst Difei Yang views FDA approval of Pacira Pharmaceuticals (PCRX) Exparel in nerve block as positive for Heron Therapeutics' (HRTX) HTX-011. The FDA updated the label information of Exparel to include detail on the opioid sparing properties of the drug, which appear "modest and potentially not clinically meaningful," Yang tells investors in a research note. This is in contrast to HTX-011, which has demonstrated "superior opioid sparing properties" in a number of studies including the latest Phase 3 trials, the analyst contends. Yang keeps a Buy rating on Heron with a $35 price target.
News For HRTX;PCRX From the Last 2 Days
There are no results for your query HRTX;PCRX